AstraZeneca's anti-IL-33 antibody tozorakimab met its primary endpoint in the Phase 3 Oberon and Titania trials, significantly reducing the annualized rate of moderate-to-severe COPD exacerbations compared to placebo.13
Success was observed in a broader-than-expected population, including former and current smokers across all blood eosinophil counts and lung function severity stages.123
Tozorakimab demonstrated a favorable safety profile and was generally well-tolerated.13
Unlike competitors like Sanofi/Regeneron's itepekimab and Roche's astegolimab, which had mixed results, tozorakimab showed consistent efficacy across trials.13
Topline results announced on March 27, 2026; full data to be presented at an upcoming medical meeting.13
AstraZeneca is conducting additional Phase 3 trials (Prospero and Miranda) in COPD, with results expected in the first half of 2026.13
Analysts highlight tozorakimab's potential for peak sales of $3-5 billion and broader patient eligibility compared to therapies like Dupixent.13
Sources:
1. https://www.fiercebiotech.com/biotech/astrazeneca-delivers-dream-result-phase-3-copd-hits-breathe-life-class-rocked-flops
2. https://www.biopharmadive.com/news/astrazeneca-lung-drug-gets-surprise-win-in-copd-trials/815949/
3. https://www.clinicaltrialsarena.com/news/astrazeneca-copd-tozorakimab-phase-iii-oberon-titania-results/